Home › Compare › RFHRF vs MRK

RFHRF vs MRK: Dividend Comparison 2026

RFHRF yields 14285.71% · MRK yields 3.25%● Live data

vsPost on X →
After 10 years · $10,000 invested · DRIP enabled
🏆 RFHRF wins by $1868328188208921344.00M in total portfolio value
10 years
RFHRF
RFHRF
● Live price
14285.71%
Share price
$0.01
Annual div
$2.00
5Y div CAGR
0%
Payout ratio
50%
After 10 yrs · $10,000 · DRIP
Portfolio value
$1868328188208921344.00M
Annual income
$1,842,950,648,126,759,800,000,000.00
Full RFHRF calculator →
MRK
Merck & Co. Inc.
● Live price
3.25%
Share price
$94.80
Annual div
$3.08
5Y div CAGR
8.2%
Payout ratio
42%
After 10 yrs · $10,000 · DRIP
Portfolio value
$30.7K
Annual income
$950.29
Full MRK calculator →

Portfolio growth — RFHRF vs MRK

📍 RFHRF pulled ahead of the other in Year 1

Annual dividend income

🛡️

Recession Test — Did They Cut Dividends?

How each stock treated shareholders during the 3 biggest crises of the last 20 years

Crisis PeriodRFHRFMRK
2008–2009
GFC
— No data— No data
2020 Q1–Q2
COVID
— No data— No data
2022 Q4
Rate Hike
— No data— No data
Based on dividend payment history. "Increased" = dividend grew during crisis. "Maintained" = held within 3%. "Cut" = reduced by more than 3%.
📅

Dividend Calendar Overlap

Combined, RFHRF + MRK cover 0 of 12 months — good coverage

Jan
—
Feb
—
Mar
—
Apr
—
May
—
Jun
—
Jul
—
Aug
—
Sep
—
Oct
—
Nov
—
Dec
—
RFHRF pays
MRK pays
Both pay
Neither
💰

Tax Bracket Optimizer

Which stock is actually better after tax? Adjust your rate to find out.

RFHRF
Annual income on $10K today (after 15% tax)
$1,214,285.71/yr
After 10yr DRIP, annual income (after tax)
$1,566,508,050,907,746,000,000,000.00/yr
MRK
Annual income on $10K today (after 15% tax)
$276.16/yr
After 10yr DRIP, annual income (after tax)
$807.75/yr
At 15% tax rate, RFHRF beats the other by $1,566,508,050,907,746,000,000,000.00/year in after-tax income after 10 years on $10,000
⚖️

Lazy Portfolio Split Optimizer

What's the optimal mix of RFHRF + MRK for your $10,000?

RFHRF: 50%MRK: 50%
100% MRK50/50100% RFHRF
Portfolio after 10yr
$934164094104460672.00M
Annual income
$921,475,324,063,379,900,000,000.00/yr
Blended yield
98.64%
📊

Analyst Conviction Gap

Where Wall Street is most bullish on MRK right now

RFHRF
No analyst data
Altman Z
-693.6
Piotroski
1/9
MRK
Analyst Ratings
25
Buy
11
Hold
1
Sell
Consensus: Buy
Price Target
$128.54
+35.6% upside vs current
Range: $100.00 — $150.00
Altman Z
4.0
Piotroski
6/9
Analyst ratings via FMP. Altman Z-Score: >3.0 safe, 1.81–3.0 grey zone, <1.81 distress. Piotroski: 7–9 strong, 0–3 weak.
🏛️

Copy Congress — What Are Politicians Buying?

Senate & House STOCK Act disclosures (last 90 days)

RFHRF buys
0
MRK buys
0
No recent congressional trades found for RFHRF or MRK in the last 90 days.
STOCK Act mandates disclosure within 45 days of transaction. Data via FMP.Full tracker →
MetricRFHRFMRK
Forward yield14285.71% ✓3.25%
Annual dividend / share$2.00$3.08 ✓
Payout ratio50%42% ✓
1-year div growth0%5.5% ✓
5-year div CAGR0%8.2% ✓
Portfolio after 10y$1868328188208921344.00M ✓$30.7K
Annual income after 10y$1,842,950,648,126,759,800,000,000.00 ✓$950.29
Total dividends collected$1866648039868218112.00M ✓$6.1K
Payment frequencyquarterlyquarterly
SectorStockHealthcare

Year-by-year: RFHRF vs MRK ($10,000, DRIP)

YearRFHRF PortfolioRFHRF Income/yrMRK PortfolioMRK Income/yrGap
1← crossover$1,439,271$1,428,571.43$11,192$351.54+$1.43M → RFHRF
2$193,699,090$192,159,069.24$12,524$392.70+$193.69M → RFHRF
3$24,376,441,818$24,169,183,791.94$14,015$438.65+$24376.43M → RFHRF
4$2,868,716,750,186$2,842,633,957,441.24$15,682$489.96+$2868716.73M → RFHRF
5$315,716,708,842,374$312,647,181,919,674.60$17,547$547.23+$315716708.82M → RFHRF
6$32,495,195,455,130,188$32,157,378,576,668,850.00$19,632$611.16+$32495195455.11M → RFHRF
7$3,128,044,259,554,657,300$3,093,274,400,417,667,600.00$21,963$682.53+$3128044259554.64M → RFHRF
8$281,631,115,249,329,080,000$278,284,107,891,605,600,000.00$24,571$762.18+$281631115249329.06M → RFHRF
9$23,717,327,179,590,366,000,000$23,415,981,886,273,583,000,000.00$27,486$851.08+$23717327179590368.00M → RFHRF
10$1,868,328,188,208,921,400,000,000$1,842,950,648,126,759,800,000,000.00$30,745$950.29+$1868328188208921344.00M → RFHRF

RFHRF vs MRK: Complete Analysis 2026

RFHRF — Stock

Renforth Resources Inc. engages in the acquisition, exploration, and development of mineral properties in Canada. It owns interests in the Surimeau District battery metals property in Quebec; Parbec gold deposit, a surface gold deposit in Malartic, Quebec; the Malartic West property, the site of a copper/silver discovery; and the Nixon-Bartleman property that hosts gold located to the west of Timmins Ontario. The company was formerly known as Wycliffe Resources Inc. Renforth Resources Inc. is headquartered in Pickering, Canada.

Full RFHRF Calculator →

MRK — Healthcare

Merck is a Dividend Aristocrat with 14+ consecutive years of increases. Keytruda (pembrolizumab) is the world's best-selling cancer drug and drives exceptional cash generation. The company's oncology and vaccines pipeline provides long-term growth visibility beyond the Keytruda patent cliff in the 2030s.

Full MRK Calculator →
📬

Get this RFHRF vs MRK comparison by email

Save your analysis + weekly dividend insights. Free forever.

More comparisons

RFHRF vs SCHDRFHRF vs JEPIRFHRF vs ORFHRF vs KORFHRF vs MAINRFHRF vs JNJRFHRF vs ABBVRFHRF vs PFE

⚠️ Educational purposes only. Not financial advice. Congressional trades sourced from SEC STOCK Act filings via FMP. Past performance does not guarantee future results.